My understanding is that they are interim results and they may be in talks with the FDA as early as March next year re design of Phase 2c/3 trials.
@Tony barber
That is exactly what Gary said today on the below video at the 6.20 mark - we'll have 12months of data come March 2025 and then we will go to the FDA to discuss the pivotal registration study. They expect to do that in Q2, expecting an answer/agreement from the FDA around the middle of 2025.
https://juststocks.com.au/syntara-ceo-gary-phillips-talks-juststocks-video-through-positive-interim-data-in-lead-myelofibrosis-trial/
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
-0.004(7.55%) |
Mkt cap ! $79.62M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.3¢ | 4.9¢ | $389.2K | 7.789M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 777864 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 489173 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| SNT (ASX) Chart |